Risks

Negative interest coverage and elevated debt-to-equity versus larger medtech peers increase refinancing sensitivity if reimbursement or demand weakens, despite a healthy current ratio.

A 93-day cash conversion cycle versus faster-turning device peers ties up working capital, which can constrain flexibility if inventory or receivables extend further.

Inventory days near 84 versus leaner peers raise obsolescence and discounting risk, especially in a product category where product refresh cycles can pressure margins.

Net debt remains manageable on an EBITDA basis, but the negative TTM leverage metric versus cash-generative peers leaves less cushion if operating performance softens.

Opportunities

Strong current and quick ratios versus many small-cap medtech peers support commercial continuity and give MYO more operating flexibility during demand volatility.

Net debt below EBITDA versus leveraged peers improves resilience and can support share gains if competitors face tighter financing or working-capital constraints.

Working-capital intensity is elevated, but if receivables and inventory normalize versus peers, cash release could improve reinvestment capacity and margin conversion.

Relative liquidity strength can help MYO absorb reimbursement timing or customer-order swings better than peers with weaker balance sheets, supporting steadier execution.

Overall Score

MYO’s liquidity profile and modest net leverage provide some peer-relative resilience, but weak interest coverage and slower working-capital turnover keep forward positioning only moderately favorable.